Compared to 138 AML patients without a DNMT3A mutation, only the subgroup with shorter overall survival (short-lived subgroup from here on) showed a statistically significant difference in survival (P < 0.0001), while the other (long-lived subgroup) did not (P < 0.345), although a considerable deviation of its survival curve from that of the non-mutated patients was observed (Fig. 1B). The gene discussed is DNMT3A; the disease is acute myeloid leukemia.